Skip to main content
SpringerLink
Log in

Fall 68: Therapie – 75 Jahre, ♂, DM Typ 2

  • Chapter
  • First Online:
Diabetes-Therapie – informiert entscheiden

Zusammenfassung

Ein 75-jähriger Patient mit Diabetes Typ 2 seit 21 Jahren un bisher fehlenden Spätschäden möchte Empagliflozin. Wäre dies zu empfehlen?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ, Investigators E-RMT (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes care 37(6):1650–1659. https://doi.org/10.2337/dc13-2105

    Article  CAS  PubMed  Google Scholar 

  • Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC, Investigators E-RMT (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes care 36(11):3396–3404. https://doi.org/10.2337/dc12-2673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, investigators E-RPt (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes, obesity & metabolism 16(2):147–158. https://doi.org/10.1111/dom.12188

    Article  CAS  Google Scholar 

  • Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, investigators E-RHHSt (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2(9):691–700. https://doi.org/10.1016/S2213-8587(14)70120-2

    Article  CAS  PubMed  Google Scholar 

  • Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC, investigators E-RMt (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1(3):208–219. https://doi.org/10.1016/S2213-8587(13)70084-6

    Article  CAS  PubMed  Google Scholar 

  • Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC, Investigators E-RMT (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes care 37(7):1815–1823. https://doi.org/10.2337/dc13-3055

    Article  CAS  PubMed  Google Scholar 

  • Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, investigators E-RBt (2015) Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism 17(10):936–948. https://doi.org/10.1111/dom.12503

    Article  CAS  Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, Investigators E-RO (2016) Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920

    Article  CAS  PubMed  Google Scholar 

  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Investigators E-RO, Broedl UC, Inzucchi SE (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg, Deutschland

    Konstantinos Avranas

Authors
  1. Konstantinos Avranas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos Avranas .

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg, Germany

    Lars Kihm

  2. Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg, Germany

    Stefan Kopf

  3. Zentrum für Innere Medizin I und klinische Chemie, Medizinische Universitätsklinik, Heidelberg, Germany

    Peter Nawroth

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Avranas, K. (2018). Fall 68: Therapie – 75 Jahre, ♂, DM Typ 2. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_68

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-55972-7_68

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-55971-0

  • Online ISBN: 978-3-662-55972-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation